---
title: "Truist Financial Reaffirms Their Buy Rating on Vericel (VCEL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294508492.md"
description: "Truist Financial analyst Richard Newitter reaffirmed a Buy rating on Vericel (VCEL) with a $58.00 price target. Newitter, who covers the Healthcare sector, has a 6.6% average return and 48.48% success rate. The broader analyst consensus for Vericel remains a Strong Buy, with an average price target of $60.75."
datetime: "2026-07-31T11:47:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294508492.md)
  - [en](https://longbridge.com/en/news/294508492.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294508492.md)
generator: "portal-rs"
---

# Truist Financial Reaffirms Their Buy Rating on Vericel (VCEL)

In a report released today, Richard Newitter from Truist Financial reiterated a Buy rating on Vericel, with a price target of $58.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Newitter covers the Healthcare sector, focusing on stocks such as Boston Scientific, Lantheus, and Glaukos. According to TipRanks, Newitter has an average return of 6.6% and a 48.48% success rate on recommended stocks. 

Currently, the analyst consensus on Vericel is a Strong Buy with an average price target of $60.75.

### Related Stocks

- [VCEL.US](https://longbridge.com/en/quote/VCEL.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)
- [BSX.US](https://longbridge.com/en/quote/BSX.US.md)
- [LNTH.US](https://longbridge.com/en/quote/LNTH.US.md)
- [GKOS.US](https://longbridge.com/en/quote/GKOS.US.md)

## Related News & Research

- [Vericel to present at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/298319911.md)
- [Vericel Q2 2026 earnings preview](https://longbridge.com/en/news/294226819.md)
- [TD Cowen Keeps Their Buy Rating on Amgen (AMGN)](https://longbridge.com/en/news/298357051.md)
- [Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy](https://longbridge.com/en/news/298319347.md)
- [KKR buys stake in Malaysia's Avisena in healthcare push](https://longbridge.com/en/news/297986796.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**